
SynAct Pharma Q1 2025 - New Phase II Study in Dengue Fever

Redeye comments on SynAct's Q1 report, which includes the initiation of a new phase II study in Dengue fever and new patents. Costs increased compared with Q4 2024.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

SynAct Pharma Q1 2025 - New Phase II Study in Dengue Fever